Certolizumab pegol improves HRQoL in patients with Crohn's disease: Data from PRECiSE 2

被引：0
|
作者：
Feagan, B.
Keininger, D.
Coteur, G.
Schreiber, S.
机构：
[1] Robarts Res Inst, London, ON N6A 5C1, Canada
[2] Univ Kiel, Kiel, Germany
[3] SGS Life Sci Serv, Mechelen, Belgium
来源：
INFLAMMATORY BOWEL DISEASES | 2007年 / 13卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：661 / 662
页数：2
相关论文
共 50 条
  • [21] PREGNANCY OUTCOMES IN CROHN'S DISEASE PATIENTS EXPOSED TO CERTOLIZUMAB PEGOL: SAFETY DATA FROM THE SECURE REGISTRY
    Lichtenstein, Gary R.
    Lee, Scott D.
    Feagan, Brian G.
    Loftus, Edward V.
    Ng, Samson
    Dehlin, Kaitlin
    Quinn, Paul
    Coarse, Jason
    Rosario-Jansen, Theresa
    Arendt, Catherine
    Stark, Jeffrey L.
    GASTROENTEROLOGY, 2023, 164 (06) : S692 - S692
  • [22] Certolizumab Pegol for the Management of Crohn's Disease in Adults
    Rivkin, Anastasia
    CLINICAL THERAPEUTICS, 2009, 31 (06) : 1158 - 1176
  • [23] Pharmakokinetics of Certolizumab Pegol Induction in Crohn's Disease
    Wolf, Douglas C.
    Wolf, Christine
    GASTROENTEROLOGY, 2015, 148 (04) : S867 - S868
  • [24] Maintenance therapy with certolizumab pegol for Crohn's disease
    Schreiber, Stefan
    Khaliq-Kareemi, Mani
    Lawrance, Ian C.
    Thomsen, Ole Ostergaard
    Hanauer, Stephen B.
    McColm, Juliet
    Bloomfield, Ralph
    Sandborn, William J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (03): : 239 - 250
  • [25] Certolizumab pegol for induction of remission in Crohn's disease
    Yamazaki, Hajime
    So, Ryuhei
    Matsuoka, Katsuyoshi
    Kobayashi, Taku
    Shinzaki, Shinichiro
    Matsuura, Minoru
    Okabayashi, Shinji
    Kataoka, Yuki
    Tsujimoto, Yasushi
    Furukawa, Toshi A.
    Watanabe, Norio
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (08):
  • [26] Certolizumab Pegol for Active Crohn's Disease Reply
    Sandborn, William J.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2012, 10 (03) : 327 - 328
  • [27] Certolizumab pegol efficacy is greater with more recent-onset Crohn's Disease:: PRECiSE 2 results
    Sandborn, W.
    Colombel, J.
    Panes, P.
    Schoelmerich, P.
    McColm, J.
    Schreiber, S.
    INFLAMMATORY BOWEL DISEASES, 2007, 13 (05) : 672 - 672
  • [28] Changes in utility scores of patients with active Crohn's disease after certolizumab pegol 400 mg induction and maintenance (PRECiSE 2)
    Tan, Seng
    Feagan, Brian G.
    Schreiber, Stefan
    Brown, Martin C. J.
    Gerlier, Laetitia C.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2007, 102 : S485 - S485
  • [29] Fecal Calprotectin Concentration and Clinical Remission in Patients with Active Crohn's Disease Treated with Certolizumab Pegol: Results from PRECiSE 1
    Sandborn, William
    Ullman, Thomas
    Pierre-Louis, Bosny
    Binion, David
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S441 - S441
  • [30] Improved health-related quality of life after certolizumab pegol 400 mg every 4 weeks in patients with Crohn's disease: Data from PRECiSE 2
    Feagan, Brian G.
    Keininger, Dorothy L.
    Coteur, Geoffroy
    Schreiber, Stefan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S404 - S405
12345